Jefferies Remains a Buy on Evolent Health (EVH)


In a report released yesterday, Sean Dodge from Jefferies reiterated a Buy rating on Evolent Health (NYSE: EVH), with a price target of $25. The company’s shares closed yesterday at $20.20.

According to TipRanks.com, Dodge is a 1-star analyst with an average return of 0.0% and a 47.4% success rate. Dodge covers the Services sector, focusing on stocks such as Healthcare Services, Hms Holdings Corp, and Cotiviti Holdings.

Evolent Health has an analyst consensus of Strong Buy, with a price target consensus of $28.43, implying a 40.7% upside from current levels. In a report issued on July 29, Canaccord Genuity also maintained a Buy rating on the stock with a $24 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24 and a one-year low of $10.30. Currently, Evolent Health has an average volume of 903.4K.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evolent Health, Inc. engages in the provision of health care delivery and payment services. Its solutions include population health management, health plan administration and third party administration, network performance management, risk adjustment, pharmacy benefit management, analytics and performance improvement, and technology and electronic medical record integration. The company was founded by Frank J. Williams, Seth B. Blackley, and Tom Peterson in August 2011 and is headquartered in Arlington, VA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts